Taking the pain out of Bladder Cancer Workups
The Technology
Abilis Life Sciences is addressing a large unmet need in bladder cancer diagnostics with new biomarker test for bladder cancer representing over 1 million testing opportunities per year. Using a simple urine based testing format, Abilis’ business model utilizes proprietary analytics and algorithms to medical laboratories to easily offer physicians and patients a more comfortable and cost-effective tool to detect bladder cancer.
Bladder cancer is the fourth most common cancer for men in the U.S. with:
-
- 80,000 new cases diagnosed each year
- Intensive lifelong surveillance with testing 4x/year following diagnosis
- One of the most expensive cancers to treat
- >50% recurrence rates in the first five years
- $5 billion per year expenditures in the U.S.
Current guidelines call for invasive procedures and imaging tests to accurately diagnose disease. Cytology, a urine test has low accuracy and is not relied on for diagnosis. Cystoscopy, an invasive procedure done in a non-office setting, is expensive, uncomfortable and can result in adverse events extending costs. Experts recognize the potential for low-cost biomarker tests but do not recommend any current tests to give an accurate result. This demonstrates the need our test seeks to address.
We would love to hear from you. Please complete the form below and we will get back to you as soon as possible.